Capricor Therapeutics Inc (OTCMKTS:CAPR) was upgraded by equities research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Monday.

CAPR has been the topic of a number of other research reports. HC Wainwright raised their price objective on shares of Capricor Therapeutics from $2.15 to $6.50 and gave the stock a “buy” rating in a research note on Friday, September 15th. Zacks Investment Research raised shares of Capricor Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a report on Wednesday, August 16th. Finally, Rodman & Renshaw reiterated a “buy” rating and issued a $2.15 target price on shares of Capricor Therapeutics in a research note on Saturday, July 22nd. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Capricor Therapeutics presently has a consensus rating of “Buy” and an average target price of $5.48.

Capricor Therapeutics (CAPR) opened at 3.28 on Monday. The company’s market cap is $77.07 million. Capricor Therapeutics has a 1-year low of $0.63 and a 1-year high of $4.25. The stock has a 50 day moving average price of $1.49 and a 200 day moving average price of $1.67.

Capricor Therapeutics (OTCMKTS:CAPR) last issued its earnings results on Thursday, August 10th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.02. The business had revenue of $1.00 million for the quarter, compared to analysts’ expectations of $1.10 million. On average, equities research analysts anticipate that Capricor Therapeutics will post ($0.70) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Capricor Therapeutics Inc (CAPR) Rating Increased to Sell at ValuEngine” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at

A hedge fund recently raised its stake in Capricor Therapeutics stock. Virtu KCG Holdings LLC increased its holdings in Capricor Therapeutics Inc (OTCMKTS:CAPR) by 571.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 179,301 shares of the biotechnology company’s stock after purchasing an additional 152,614 shares during the quarter. Virtu KCG Holdings LLC owned 0.79% of Capricor Therapeutics worth $149,000 at the end of the most recent reporting period.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.

Receive News & Stock Ratings for Capricor Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics Inc and related stocks with our FREE daily email newsletter.